Literature DB >> 18552705

Expression, activity, and function of phosphodiesterases in the mature and immature ductus arteriosus.

Hanguan Liu1, Vincent Manganiello, Nahid Waleh, Ronald I Clyman.   

Abstract

A patent ductus arteriosus is due in large part to increased sensitivity of the premature ductus to PGE2. After PGE2 stimulation, cAMP concentrations are higher in the immature than in the mature ductus. cAMP concentrations depend on the rates of adenyl cyclase production and phosphodiesterase (PDE)-mediated degradation. We used ductus from immature (n = 25) and mature (n = 21) fetal sheep to investigate whether a developmental increase in PDE activity could explain the diminished cAMP accumulation that follows PGE2 stimulation in the mature ductus. With advancing gestation, mRNA expression of the smooth muscle PDE isoforms (PDE1A, 1B, 1C, 3A, 3B, 4D, and 5A) increased in the ductus as did their hydrolytic activities. Selective inhibitors of PDE1, PDE3, and PDE4 relaxed the mature and immature ductus in the presence of inhibitors of prostaglandin and nitric oxide production. The mature ductus required higher concentrations of each of the PDE inhibitors to inhibit its tension to the same extent as in the immature ductus. There were no developmental changes in PDE expression in the fetal aorta. In conclusion, we observed a developmental increase in cAMP and cGMP PDE activity that contributes to the decreased sensitivity of the late-gestation ductus arteriosus to vasodilators like PGE2.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18552705      PMCID: PMC2613857          DOI: 10.1203/PDR.0b013e3181827c2c

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  32 in total

1.  Characterization of PGE2 receptors in fetal and newborn lamb ductus arteriosus.

Authors:  A Bouayad; H Kajino; N Waleh; J C Fouron; G Andelfinger; D R Varma; A Skoll; A Vazquez; F Gobeil; R I Clyman; S Chemtob
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-05       Impact factor: 4.733

Review 2.  Cyclic nucleotide phosphodiesterases (PDEs): diverse regulators of cyclic nucleotide signals and inviting molecular targets for novel therapeutic agents.

Authors:  V C Manganiello; E Degerman
Journal:  Thromb Haemost       Date:  1999-08       Impact factor: 5.249

Review 3.  Cyclic nucleotide phosphodiesterases and vascular smooth muscle.

Authors:  J B Polson; S J Strada
Journal:  Annu Rev Pharmacol Toxicol       Date:  1996       Impact factor: 13.820

Review 4.  Recent advances in the study of Ca2+/CaM-activated phosphodiesterases: expression and physiological functions.

Authors:  A Z Zhao; C Yan; W K Sonnenburg; J A Beavo
Journal:  Adv Second Messenger Phosphoprotein Res       Date:  1997

Review 5.  Calcium movements, distribution, and functions in smooth muscle.

Authors:  H Karaki; H Ozaki; M Hori; M Mitsui-Saito; K Amano; K Harada; S Miyamoto; H Nakazawa; K J Won; K Sato
Journal:  Pharmacol Rev       Date:  1997-06       Impact factor: 25.468

6.  Cyclic GMP causes Ca2+ desensitization in vascular smooth muscle by activating the myosin light chain phosphatase.

Authors:  M R Lee; L Li; T Kitazawa
Journal:  J Biol Chem       Date:  1997-02-21       Impact factor: 5.157

Review 7.  Cardiovascular risk and sildenafil.

Authors:  R A Kloner
Journal:  Am J Cardiol       Date:  2000-07-20       Impact factor: 2.778

Review 8.  Modulation of the calcium sensitivity of the smooth muscle contractile apparatus: molecular mechanisms, pharmacological and pathophysiological implications.

Authors:  J P Savineau; R Marthan
Journal:  Fundam Clin Pharmacol       Date:  1997       Impact factor: 2.748

9.  Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors.

Authors:  J E Souness; G A Hassall; D P Parrott
Journal:  Biochem Pharmacol       Date:  1992-09-01       Impact factor: 5.858

10.  Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells.

Authors:  X Pan; E Arauz; J J Krzanowski; D F Fitzpatrick; J B Polson
Journal:  Biochem Pharmacol       Date:  1994-08-17       Impact factor: 5.858

View more
  11 in total

1.  Patterns of gene expression in the ductus arteriosus are related to environmental and genetic risk factors for persistent ductus patency.

Authors:  Nahid Waleh; Ryan Hodnick; Nami Jhaveri; Suzanne McConaghy; John Dagle; Steven Seidner; Donald McCurnin; Jeffrey C Murray; Robin Ohls; Ronald I Clyman
Journal:  Pediatr Res       Date:  2010-10       Impact factor: 3.756

Review 2.  Transcriptional profiling of the ductus arteriosus: Comparison of rodent microarrays and human RNA sequencing.

Authors:  Michael T Yarboro; Matthew D Durbin; Jennifer L Herington; Elaine L Shelton; Tao Zhang; Cris G Ebby; Jason Z Stoller; Ronald I Clyman; Jeff Reese
Journal:  Semin Perinatol       Date:  2018-05-10       Impact factor: 3.300

Review 3.  Inadvertent relaxation of the ductus arteriosus by pharmacologic agents that are commonly used in the neonatal period.

Authors:  Jeff Reese; Alex Veldman; Lisa Shah; Megan Vucovich; Robert B Cotton
Journal:  Semin Perinatol       Date:  2010-06       Impact factor: 3.300

4.  Oxygen-induced tension in the sheep ductus arteriosus: effects of gestation on potassium and calcium channel regulation.

Authors:  Nahid Waleh; Jeff Reese; Hiroki Kajino; Christine Roman; Steven Seidner; Donald McCurnin; Ronald I Clyman
Journal:  Pediatr Res       Date:  2009-03       Impact factor: 3.756

5.  Chronic in utero cyclooxygenase inhibition alters PGE2-regulated ductus arteriosus contractile pathways and prevents postnatal closure.

Authors:  Jeff Reese; Nahid Waleh; Stanley D Poole; Naoko Brown; Christine Roman; Ronald I Clyman
Journal:  Pediatr Res       Date:  2009-08       Impact factor: 3.756

6.  Effects of Advancing Gestation and Non-Caucasian Race on Ductus Arteriosus Gene Expression.

Authors:  Nahid Waleh; Anne Marie Barrette; John M Dagle; Allison Momany; Chengshi Jin; Nancy K Hills; Elaine L Shelton; Jeff Reese; Ronald I Clyman
Journal:  J Pediatr       Date:  2015-08-08       Impact factor: 4.406

7.  Developmental changes in the effects of prostaglandin E2 in the chicken ductus arteriosus.

Authors:  Pia Agren; Saskia van der Sterren; Angel L Cogolludo; Carlos E Blanco; Eduardo Villamor
Journal:  J Comp Physiol B       Date:  2008-08-26       Impact factor: 2.200

8.  Current Perspectives on Pathobiology of the Ductus Arteriosus.

Authors:  Jason Z Stoller; Sara B Demauro; John M Dagle; Jeff Reese
Journal:  J Clin Exp Cardiolog       Date:  2012-06-15

9.  Effects of antenatal betamethasone on preterm human and mouse ductus arteriosus: comparison with baboon data.

Authors:  Elaine L Shelton; Nahid Waleh; Erin J Plosa; John T Benjamin; Ginger L Milne; Christopher W Hooper; Noah J Ehinger; Stanley Poole; Naoko Brown; Steven Seidner; Donald McCurnin; Jeff Reese; Ronald I Clyman
Journal:  Pediatr Res       Date:  2018-07-06       Impact factor: 3.756

10.  Safety and Feasibility of Intravenous Paracetamol for Patent Ductus Arteriosus in Indomethacin-/Ibuprofen-Resistant or -Contraindicated Preterm Infants: A Case Series.

Authors:  Ayumi Oshima; Shun Matsumura; Ayaka Iwatani; Machiko Morita; Sumie Fujinuma; Yukiko Motojima; Kosuke Tanaka; Satoshi Masutani; Kazuhiko Kabe; Keiko Ueda; Fumihiko Namba
Journal:  AJP Rep       Date:  2020-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.